Ironwood Pharmaceuticals Files 8-K on Shareholder Vote Matters

Ticker: IRWD · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1446847

Ironwood Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyIronwood Pharmaceuticals Inc (IRWD)
Form Type8-K
Filed DateJun 12, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, filing-update

Related Tickers: IRWD

TL;DR

Ironwood Pharma (IRWD) filed an 8-K on shareholder vote matters. Keep an eye on the outcome.

AI Summary

Ironwood Pharmaceuticals, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of security holders as of June 10, 2025. The filing details the company's principal executive offices located at 100 Summer Street, Suite 2300, Boston, MA 02110.

Why It Matters

This filing indicates important corporate actions or decisions that have been put to a vote by Ironwood Pharmaceuticals' shareholders, which could impact the company's future direction.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of matters submitted to a vote, not an announcement of significant financial or operational changes.

Key Players & Entities

  • IRONWOOD PHARMACEUTICALS, INC. (company) — Registrant
  • June 10, 2025 (date) — Date of Earliest Event Reported
  • June 12, 2025 (date) — Date of Report
  • 100 Summer Street, Suite 2300 (location) — Principal executive offices
  • Boston, Massachusetts (location) — Principal executive offices
  • 02110 (location) — Zip code of principal executive offices

FAQ

What specific matters were submitted to a vote of Ironwood Pharmaceuticals' security holders?

The filing states that it is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating that matters were submitted to a vote, but the specific details of those matters are not provided in the excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 10, 2025.

What is the official filing date of this 8-K report?

The official filing date of this 8-K report is June 12, 2025.

Where are Ironwood Pharmaceuticals' principal executive offices located?

Ironwood Pharmaceuticals' principal executive offices are located at 100 Summer Street, Suite 2300, Boston, Massachusetts 02110.

What is the Commission File Number for Ironwood Pharmaceuticals?

The Commission File Number for Ironwood Pharmaceuticals is 001-34620.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding IRONWOOD PHARMACEUTICALS INC (IRWD).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.